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Jesús Jiménez-Barbero *bgh
This review provides an extensive summary of the effects of carbohydrate fluorination with regard to
changes in physical, chemical and biological properties with respect to regular saccharides. The specific
structural, conformational, stability, reactivity and interaction features of fluorinated sugars are described,
as well as their applications as probes and in chemical biology.
1 Introduction
Carbohydrates are essential molecules for life. However, in
contrast to the other important classes of biomolecules, their
broad significance beyond as an energy source has been ques-
tioned until recently. This has been due to the difficulties
associated with their study, caused both by their structural
and chemical complexity as well as their non-template driven
biosynthesis. Their structural roles in plants and in bacterial
cell walls have been long known, however their key roles in
immune regulation processes, cell–cell interactions (e.g., ferti-
lization, inflammation)1,2 or in host–pathogen interactions3 have
only become clear more recently. In addition, their relationship
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Jiménez-Barbero’s group. In 2014
she moved to CIC bioGUNE in the
Basque Country, and since December 2015 she is a Ramón y Cajal
Fellow. Her research interests are focused on the study of glycan–
protein interactions through a multidisciplinary approach, with a
special focus on NMR techniques.





































































































View Journal  | View Issue
3864 | Chem. Soc. Rev., 2020, 49, 3863--3888 This journal is©The Royal Society of Chemistry 2020
with different diseases, such as cancer,4–7 infection, and auto-
immunity,8 is nowadays well-established and is a research area
under intense development.
The progress made in the last decades in Glycoscience,9
advancing our understanding on the functional role of the
molecular recognition processes of sugars by lectins and antibodies,
as well as on the chemical and structural details of the enzymatic
machineries for their processing has brought about the emerging
field of glycomimetics.10 These synthetic sugar analogues, potential
drug candidates, are small molecules designed to interact with
glycan-binding or glycan-processing proteins.11 They are structu-
rally related to carbohydrates but endowed with adapted
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properties through chemical modifications.12 One of the most
employed alterations consists in introducing fluorine, the less
abundant halogen in metabolites in Nature, but most abundant
in pharmaceuticals,13–15 where its strategic incorporation
is part of the drug development process to optimise physico-
chemical, adsorption, and distribution properties.16,17
However, the first examples of the employment of fluorine-
containing sugar analogues typically had no drug design
ambitions, but were used as probes for studying glycan–protein
interactions. In particular, early studies utilized N-fluoro-
acetylglucosamine derivatives as probes for binding to different
proteins, and exploited 19F chemical shift perturbations or
line broadening effects upon binding.18–20 Several authors
proposed to systematically substitute every –OH of the pyranose
rings by a fluorine atom as a probe for deducing hydrogen
bonding networks in sugar–receptor complexes.21–26
These pioneering works paved the way for further develop-
ments, which continue evolving, in which fluorine is intro-
duced in sugar molecules not only for studying glycan binding
phenomena, but also for interrogating glycosylation reactions
(enzymatic and non-enzymatic), to stabilize glycosides, or as a
manner to develop glycosidase inhibitors. This review will focus
on the use of fluorinated carbohydrate derivatives in the
frontier between chemistry and biology, and includes a brief
overview on how fluorination influences the properties of
saccharides. The use of fluorinated iminosugars has been
reviewed recently27 and is not included here. The application
of 19F NMR in the structural and conformational determination
of fluorinated sugar derivatives has also been reviewed and will
not be covered here.28
2 The different types of sugar
fluorination
Sugar fluorination usually refers to the replacement of a
hydroxyl group by a fluorine atom, which formally is a ‘deoxy-
fluorination’ operation. Perhaps the most famous example is
2-deoxy-2-fluoroglucose 2.1 (Fig. 1), whose 18F analogue is one
of the most used PET imaging agents. However, there are other
sugar fluorination options: in gemcitabine 2.2, an anti-cancer
agent, a secondary alcohol is replaced by a CF2-group, formally
a ‘deoxydifluorination’ operation. Sugar fluorination, in which
a C–H is replaced by C–F, is also possible, and mono-, di- and
trifluorination processes have all been described. The most
known examples include 6,6,6-trifluorofucose 2.3, and
3-fluorinated sialic acid 2.4. Note that in the latter, C3 now
becomes stereogenic (see below). Finally, the substitution of
the endo or exocyclic (anomeric) oxygen for CHF/CF2 has also
been described,29 generating fluoro-C-glycosyl compounds (O1)
or fluoro-carbasugars (O5). An example of the latter is 2.5. There
are also other types, such as C–H for C–RF (RF is perfluoroalkyl)
modifications leading to branched sugar derivatives,30 which will
not be covered here.
As indicated above, a deoxyfluorination modification of a sugar
is indicated by the prefix ‘deoxy’. Equally, if fluorination of a sugar
is not accompanied by a deoxygenation reaction, then the position
of fluorination is indicated. Hence, 2.6 is 6-fluorofucose (Fig. 2),
although 6-deoxy-6-fluorogalactose is also correct. However, 2.1
should not be referred to as ‘2-fluoroglucose’, as this name
corresponds to 2.7. Structure 2.7 is unstable and will decompose
to the corresponding 2-keto derivative. However, fluorination at
the 5-position as in 2.8 is possible. Although from a nomenclature
point of view, 2.9 can thus be named ‘2-deoxy-2,2-difluoroglucose’,
due to the loss of stereogenicity at C2, convention dictates that
deoxysugar nomenclature is followed. Hence, 2.9 is referred to as
2-deoxy-2,2-difluoro-D-arabino-hexopyranose.
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Interestingly, 3-fluorinated sialic acid is often named after
its C3-deoxyfluorinated nonulosonic acid derivative. Hence, 2.4
is named 5-acetamido-3,5-dideoxy-3-fluoro-D-erythro-L-manno-
2-nonulopyranosonic acid. Using sialic acid as a naming base,
the configuration at C3 needs to be specified, leading to
(3R)-3F-Neu5Ac. However, a much more convenient way has
been used for naming 3-fluorinated sialic acids by referring
to the orientation of the fluorine substituent on the sialic
acid chair conformation. Compound 2.4 is then named
3F(ax)-Neu5Ac. The difluorinated 2.10 is named according to
carbasugar nomenclature as indicated.31
3 Influence of carbohydrate
fluorination on physical properties
3.1 The fluorine atom and the C–F bond
Oxygen and fluorine are the two most electronegative atoms,
but their difference in electronegativity results in a number of
different properties. While they have a similar size, the higher
ionization potential of the fluorine lone pair makes it a worse
hydrogen bond acceptor with less polarizable lone pairs than
oxygen. While the divalent oxygen allows for the presence of a
covalent O–H bond, this is not the case for the monovalent
fluorine, so a deoxyfluorination leads to the loss of hydrogen
bond donating capacity at that position. Hence, this leads to a
C–F group being much more hydrophobic than an alcohol
group. A CH–OH is larger than a CH–F substituent, but similar
in volume to a CF2-group.
Due to its high electronegativity and absence of any other
substituent (the alcohol oxygen also has an O–H bond), the C–F
bond is highly polarized, which will affect the electron density
of the carbohydrate structure. This is particularly pronounced
when a C–H group is changed for C–F. Hence, adjacent
functional groups are affected, which has consequences for
their interactions with proteins.
3.2 The influence on carbohydrate structure and
conformation
The conformation of the ligand is of great importance when
considering protein–carbohydrate interactions.32 The presence
of the fluorine may, in principle, affect the conformational
properties of the fluorine-containing ligands at different levels,
the monosaccharide rings, the pendant groups, the glycosidic
linkages; as well as global physicochemical properties.
3.2.1 The pyranose chair conformation. The conformation
of fluorinated carbohydrate derivatives has been extensively
studied in solution and in the solid state. In general, fluorina-
tion does not lead to significant distortion of the pyranose
conformation, even when multifluorinated, such as in 3.1
(Fig. 3).33 Crystal structures of free trideoxytrifluorinated sugars
such as the glucose 3.2,34 the corresponding altrose34a and
galactose34 (all as b-anomers), as well as in derivatives of
the trifluorinated allo-, manno-, and talopyranoses35 show
4C1-conformations. However, slight distortions are possible
with 1,3-coaxial C–O and C–F bonds, which was shown for
3.3.36 Many other crystal structures of such heavily fluorinated
derivatives,36 including that of a hexafluorinated pyranose
Fig. 2 Typical nomenclature employed for fluorinated carbohydrate derivatives.
Fig. 3 Ring conformation of fluorinated carbohydrate derivatives.
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3.4,37 have been reported, again all in 4C1-conformations.
In pentopyranosyl fluorides, the strong anomeric effect invol-
ving the anomeric C–F bond has been shown to lead to a chair
inversion, even in the triacetylated b-D-xylopyranosyl fluoride
3.5 where the ring inversion leads to three axial ester groups.38
Only a few conformational studies have been performed for
fluorocarbapyranoses. Nevertheless, conformational studies
of a- and b-gem-difluorocarbaglucose, galactose and mannose
derivatives using NMR, molecular modeling and, when possi-
ble, X-ray crystallography indicated that the presence of the CF2
moiety in the ring does not significantly affect the 4C1 chair
conformation compared to the regular sugar.39 Furthermore, a
study on 5a-gem-difluorocarbaidoses showed that it retained
the conformational plasticity of its oxygenated counterpart.40
In the case of fluoro-C-glycosides, the situation is more diverse,
as 4C1 but also other conformations (
1C4 and
1S3) were observed
in solution with galactose analogues.41
3.2.2 The exocyclic hydroxymethyl group. The C4-
configuration strongly determines the exocyclic C5–C6 con-
formational profile, with the conformation featuring aligned
C–O bonds generally being disfavoured,42 a situation which is
expected to be similar upon deoxyfluorination. The vicinal
3JH5–F6 coupling constant is particularly diagnostic for this
exocyclic C5–C6 bond conformation. The preferred conformation
of the exoxyclic fluoromethyl group in 6-deoxy-6-fluoroglucose 3.6,
as shown in Fig. 4, had already been determined in the late
1960’s,43 as this was possible with the spectrometers at the time.
For the galactose derivative 2.6, the gt conformation was estab-
lished to be the most abundant, with a lesser contribution
from the tg-conformer (not shown).44 For the 4,6-dideoxy-4,6-
difluorinated GalNAc derivative 3.7, the gt conformation was also
proposed as the major species in solution,45 and the preferred gg
conformation in 4,6-difluorinated glucose derivatives was also
demonstrated.46 Interestingly, the crystal structure of a glycoside
of the 2,3,4,6-tetrafluorinated galactose derivative 3.8 was shown
to feature a gg conformation, but a gt conformation was proposed
in the solution phase.36
3.2.3 Fluorinated C-glycosides and carbasugars: glycosidic
bond conformation. In O-glycosides, the stereoelectronic
stabilization caused by the exo-anomeric effect, characterized
by an overlap between an anomeric oxygen lone pair and the
s*C1–O1 orbital, as well as a steric repulsion, leads to a specific
‘‘exo’’ conformation of the glycosidic bond (Fig. 5(a) illustrates
a b-glycoside). The deletion of one oxygen atom from the acetal
of the glycoside removes the anomeric effects leading to
a change in conformational behavior.47 For CH2-glycosides
(and for carbasugars), there are no noteworthy stereoelectronic
effects, and the conformational distribution is only ruled by the
minimization of steric repulsions. Consequently, they display
more flexibility than regular oligosaccharides, resulting in a
concomitant entropy penalty in molecular recognition events.48
However, replacing the oxygen atom by a fluorine-containing
methylene group in C-glycosides introduces the possibility of
fluorine gauche effects. This stereoelectronic effect is based on
a stabilising sC–H/s*C–F and, to a lesser extent, a sC–C/s*C–F
hyperconjugation, and is much related to the anomeric effect
itself.49 Indeed, it has been shown to play a role in the
conformation of fluorinated molecules.49 This effect is illu-
strated in Fig. 5(b) for a CF2-glycoside, showing the two con-
formations that allow for the most stabilising hyperconjugation
situations.
Hence, the maximisation of s*C–H/s*C–F and sC–C/s*C–F
interactions might therefore stabilize ‘‘non-natural’’ conforma-
tions that would be high in energy for the parent O-glycoside,
which has been demonstrated for a number of fluorinated
C-glycosides including 3.941 (Fig. 6) and CHF and CF2
C-glycoside analogues 3.12–3.14 of b-Gal-(1,1)-a-Man 3.10.50
In the exo-anomeric effect, hyperconjugation occurs between
a lone pair orbital of the anomeric oxygen with the s*C1–O5
bond, which is more favourable than with the s*C1–C2 bond.
This can be attributed to the distinct polarization of the C1–O5
bond, which results a larger s* orbital centered on the less
electronegative atom of the polarized bond. (3.15, Fig. 7a). This
distinction disappears with carbasugars in which the C1–C2
and C1–C5a have the same polarity, therefore no preferential
conformation is observed (3.16, Fig. 7b). In order to restore the
conformational restriction caused by the exo-anomeric effect
with carbasugars, a CF2-carbasugar as a ‘‘stereoelectronic’’
mimic for O5 was investigated. Indeed, it was demonstratedFig. 4 Preferred conformations of the exocyclic fluoromethyl group.
Fig. 5 The anomeric and fluorine gauche effects determining anomeric
conformation.
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that the replacement of the endocyclic oxygen atom by a CF2
group in maltose induced a polarization of the C1–CF2 bond,
which was shown to restore the exo-anomeric effect, and the
preferential exo conformation (3.17, Fig. 7c).51
3.2.4 Anomeric and ring equilibra. A systematic study
involving the determination of the anomeric ratios of glucose,
galactose and their monodeoxyfluorinated analogues (Table 1)
showed that there was no significant variation upon deoxy-
fluorination.52 However, in all cases, deoxyfluorination lead to
an increased preference for the axial anomer, which was
explained by the larger electron withdrawing effect of fluorine
compared to that of OH. This results in an increased deshielding
of the nearby axial C–H bonds, resulting in a reduced
1,3-diaxial repulsion (or increased intramolecular electrostatic
interaction). There was also a correlation between the combined
increase in chemical shift of H3 and H5 (compared to that of the
nonfluorinated parent) and the free energy difference between the
anomers (as calculated from the ratio of anomers).
The solution-phase composition of galactose and its deoxy-
fluorinated analogues, in particular the equilibrium between
the pyranose and furanose forms, has been extensively studied
in the context of investigations of the enzyme galactose mutase
(Table 2). In addition to the minor differences discussed above,
galactose deoxyfluorination at the 2 or 3-position decreases the
amount of furanose,53 an effect also observed for talose.54
However, galactose deoxyfluorination at the 6-position (to give
6-fluorofucose) results in an increase of furanose content,55 an
effect that is further magnified upon trifluorination at this
position.56 The same can be seen when the C6-hydroxymethyl
group in altrose is replaced by a trifluoromethyl group.56 It is
likely that fluorination at the 6-position reduces the nucleo-
philicity of the 5-OH group, favouring involvement of the 4-OH
group in the hemiacetal ring formation.
The enzyme mutarotase catalyses the equilibrium between
sugar anomers. Using two-dimensional exchange spectroscopy
(2D-EXSY) at equilibrium, it was shown that mutarotase cata-
lyses the rapid (time scale of a few seconds) exchange between
the anomers of 4-deoxy-4-fluoro-D-glucose, but not that of
glucose analogues with fluorination at the 2- and/or 3-position.58
This was explained by the electron withdrawing effect destabilizing
the required free aldehyde group of the open form. Nevertheless,
dissolution of a pure crystal of the b-anomer of 6-deoxy-6,6,6-
trifluoroaltrose was reported to ‘soon’ give the equilibrium
mixture.54
3.3 The stability of the glycosidic bond
The stronger inductive effect of fluorine compared to OH
renders oxocarbenium formation more difficult for fluorinated
carbohydrate derivatives compared to the native parents.59 This
was realised very early on through hydrolysis studies of glycosyl
phosphates and dinitrophenylglycosides.60 In general, hydro-
lysis rates decrease in the following order (Table 3): parent 4
6-deoxyfluoro 4 3-deoxyfluoro 4 4-deoxyfluoro 4 2-deoxyfluoro
(with an inverse order for the deoxygenated analogues). Through
a detailed study of dinitrophenylglycoside hydrolysis, it was
established that the hydrolysis rates are largely dictated by the
field effect on the oxocarbenium transition state, with significant
electron deficient character on O5. Interestingly, dideoxydifluori-
nation at the 3 or 4 and 6-positions leads to a hydrolysis rate
equivalent to that of deoxyfluorination at 2-position, and dide-
oxymonofluorination actually leads to a higher rate constant
than that of the parent derivative.
The destabilizing effect on oxocarbenium transition state
formation has been successfully exploited for ‘mechanism-
based’ enzyme inhibition (first reports,61 reviews62). Deoxy-
fluorinated carbohydrates which display an excellent leaving
group at the anomeric position can still undergo reaction with
nucleophiles, including the catalytic nucleophile of retaining
glycosidase enzymes, in contrast to the thus formed glycosyl-
enzyme intermediate, which is formally a – less reactive –
anomeric ester derivative. Hence, for glycosidases for which
the hydrolysis of the glycosyl enzyme intermediate with the
Fig. 6 Substrates investigated for glycosidic bond conformation.
Fig. 7 Schematic representation of the lone pair–s* interactions respon-
sible for the exo-anomeric effect and exo conformation in glycosides and
gem-difluoro-carbaglycosides.
Table 1 Anomeric composition of glucose, galactose, and their mono-





%a %b %a %b
— 35 65 31 69
2 45 55 42 58
3 48 52 43 57
4 44 56 37 63
6 43 57 37 63
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natural substrate is rate-determining, inactivation is possible
by employing a fluorinated analogue, typically using fluorina-
tion adjacent to the anomeric center but also at the 5-position.
In this regard, an interesting illustration of the effects of
fluorination on anomeric reactivity is shown with the fluori-
nated maltoses 3.1863 and 3.1964 (Fig. 8), which were investi-
gated as mechanism-based enzyme inhibitors for the maltosyl
transferase GlgE1 from Streptomyces coelicor. While 3.18 was
shown to form the covalent intermediate by reaction with the
relevant nucleophilic Asp residue,63 the enzyme was able to
subsequently effect hydrolysis. This could only be prevented
with a E423A point mutation. However, with the trifluorinated
maltose 3.19,64 the increased deactivation resulting from
C2-difluorination rendered it too unreactive to react with the
enzyme. Interestingly, this allowed crystallization of 3.19 in
complex with GlgE1 (see below).
Hence, disaccharides with a 20-deoxyfluorination modifica-
tion can still react with glycosidases, causing mechanism-based
inhibition. Indeed, if the binding energy component provided
by the natural aglycon (or the reducing sugar moiety) is large
enough, then the rate of the initial reaction of the catalytic
nucleophile with the fluorinated glycoside derivative can
be increased. This fact has been exploited for the design of
selective mechanism-based glycosidase inhibitors.65
The same deactivating effect on oxonium formation would
result in saccharides modified by deoxyfluorination at the non-
reducing 2-position(s) being stabilized against both acid-catalysed
and enzymatic hydrolysis. Recent examples of this strategy are
shown in Fig. 9.
Chen and coworkers showed that deoxyfluorination of the
5-OH of KDN in sialosides 3.20 and 3.21 leading to 3.22 and
3.23 did not significantly change the activity of the multi-
functional Pasteurella multocida sialyltransferase (PmST1),66
Table 2 Anomeric composition
Mono-saccharide Modification a-Pyranose b-Pyranose a-Furanose b-Furanose Total furanose Ref.
Gal — 31.8 60.5 3.1 4.6 7.7 53
2F 41.0 55.7 1.0 2.2 3.2 53
3F 40 58 0.7 1.6 2.3 53
6F 30 56 5 8 13 55
6-Deoxya 28 67 5 5 (3.7) 56 and 57
6,6,6-Tri-Fa 29 43 11 17 28 56
Alt — 30 41 18 11 29 56
6,6,6-Tri-F 14 20 33 33 66
Tal — 42.0 29.0 16.0 13.0 29 57
2F 50 37 8.0 5.0 13 54
a Fucose.
Table 3 Observed first-order rate constants for acid-catalysed hydrolysis

















Fig. 8 Fluorinated maltose derivatives as mechanism-based inhibitors.63,64 Fig. 9 Stabilisation of the glycosidic bond by fluorine introduction.
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which also possesses sialidase activity. In contrast, PmST1
displayed a significantly increased sialidase activity towards
the 5-deoxygenated disaccharide 3.24, but not towards 3.25.
It was concluded that the hydrogen bonding properties of the
5-OH group were not important for PmST1 activity. Hoffmann-
Röder and coworkers investigated the enzymatic stability of the
Thomson–Friedenreich antigen derivatives 3.26 and 3.27.67
A b-galactosidase catalyzed the hydrolysis of 3.16 with a half-
life of approximately 3 h, while the fluorinated 3.27 remained
intact over 7 h of incubation. Wong and coworkers showed that
in contrast to 3.28, sialidases from C. perfingens and V. cholera
were inactive towards 3.29.68a Also, 3.29 did not significantly
inhibit the hydrolysis of 3.28.68
3.4 Lipophilicity
The lipophilicity of a compound is measured experimentally by
determining its partition coefficient P between 1-octanol and water,
and expressed as log P.69 It reflects a balance of the hydrophobic and
hydrophilic features of the compound. This value is widely used in
medicinal chemistry as a measure for membrane permeability, with
optimum values between +1 and +3 (for orally available drugs).
It also impacts affinity to proteins as it roughly relates to the extent
of hydrophobic desolvation energy involved in the binding process.
Hence, changing a compound’s lipophilicity will affect affinity.
Carbohydrates are very hydrophilic, resulting in low log P
values. However, there are very few experimental data available,
in part reflecting the difficulty in measuring accurate sugar
concentrations. The log P of Glc is reported to be 2.82 to
3.24.70 The replacement of hydroxyl groups by fluorine is
expected to increase a compound’s lipophilicity. Using a
19F NMR based method, the log P value has been experimentally
quantified for a range of deoxyfluorinated carbohydrate deri-
vatives (Fig. 10).35,46,71
For Glc derivatives, monodeoxyfluorination leads to a log P
increase of almost an order of magnitude (2.21 for 2.1),
raising by another order of magnitude for a dideoxydifluorina-
tion (1.11 for 3.30). Dideoxytetrafluorination leads to yet
another order of magnitude increase (0.32 for 3.31), as does
trideoxytrifluorination in 3.2. The position of the fluorination
(e.g. 6-deoxy-6-fluoroglucose, log P 2.36) and the carbohydrate
stereochemistry (e.g. 2-deoxy-2-fluorogalactose, log P 2.37)
also impact on the log P value (not shown). The lipophilicity
of 2,3,4-trideoxy-2,3,4-trifluorinated monosaccharide deriva-
tives can vary considerably, with the talose derivative 3.33 being
much more polar compared to the Glc analogue 3.32.
4 Molecular interactions influenced by
fluorination
4.1 CH–p interactions
Hydrogen bonding and CH–p interactions are the two key
direct protein–sugar interactions, and both are influenced by
fluorination. CH–p interactions are of paramount importance
to stabilize the corresponding complexes72,73 and their impor-
tance is also substantiated by the relative abundance of
aromatic amino acids in the binding pocket of lectins.74
CH–p interactions are usually described as weak polar inter-
actions in which the delocalized electron density of sp2-
hybridized aromatic moieties acts as an acceptor, while the
hydrogen atom on the polarized C–H moiety acts as donor.75
In sugars, the CH donor groups are polarized by the geminal
hydroxyl groups, making the CH-vector a suitable moiety for
establishing polar interactions. Although oxygen and fluorine
are the two most electronegative atoms, their intrinsic differences
could influence their relative ability to participate in CH–p inter-
actions with proteins, as demonstrated for hydrogen-bonded
interactions. Moreover, in hydroxyl groups, the oxygen is already
attached to a hydrogen atom, which reduces the electron with-
drawing character of the C–O bond. Thus, the key question here is
how fluorine influences the capacity of deoxyfluorosugars to
participate in CH–p interactions.76 A simple NMR-based experi-
mental approach has been used to evidence the preferred orienta-
tion of aromatic rings when interacting with saccharides in water
solution.77
A dynamic combinatorial approach for the study of carbo-
hydrate/aromatic interactions has been presented.78 The
experimental results from the analysis of a large data set of
chemically diverse carbohydrate–aromatic complexes allowed
the accurate determination of the structure–stability relation-
ship that governs these weak interactions. The influence of the
equatorial or axial orientation of the sugar polar groups on the
Fig. 10 Lipophilicities of fluorinated sugar derivatives.35,46,71

































































































This journal is©The Royal Society of Chemistry 2020 Chem. Soc. Rev., 2020, 49, 3863--3888 | 3871
strength of the carbohydrate–aromatic complex was also deter-
mined by using punctual OH - F substitutions. In particular,
2-deoxy-2-fluoro mannoside derivative showed enhanced
stabilization properties with respect to the gluco-configurated
analogue, suggesting that equatorial polar moieties might be
involved in repulsive interactions with the aromatic units.
Moreover, the introduction of a fluorine substituent at the
anomeric center modulates the electron density at the endo-
cyclic oxygen, thus fine-tuning the stability of the complexes
and the orientation of the pyranose ring with respect to the
aromatic moiety. These fundamental studies demonstrated the
influence of fluorine substitution on CH/p interactions and
provided the impetus to further investigate the role of ligand
fluorination in carbohydrate–lectin interactions.
Additional evidences regarding the role of fluorine substitu-
tion in enhancing methyl–p interactions have been presented,
along with an overall study that correlated the enthalpy con-
tribution of these weak interactions as function of the hydrogen
polarizability by none, one, or two fluorine substituents.79 The
contribution from these studies lies in the elucidation of the
polar character in methyl–p interactions in sugar/receptor
recognition, thus complementing the advances in the study of
the direct pyranose/aromatic stacking. The authors studied the
interaction of wheat-germ agglutinin (WGA), a model lectin,
with acetylated amino sugars by NMR and molecular modeling.
DFT-based theoretical calculations suggested that the presence
of fluorine atoms at the acetamide group should enhance
the interaction between the fluorinated analogues and the
aromatic residues of the protein, given the polarization of the
C–H bond at the CHF2CONH– and CH2FCONH– functions by
the electron-withdrawing fluorine atoms. On the contrary, the
absence of any CH–p donor group in CF3CONH– derivatives
should significantly reduce the binding energy due to the
unfavorable contacts of the electron-rich fluorine atoms and
the aromatic residues. To experimentally prove this hypothesis,
the authors used an NMR-based strategy and demonstrated
that the strength of the CH–p interaction significantly depends
on the polarization degree of the CH–p hydrogen donor. The
values for the binding constants (kD), derived by STD-NMR
competition experiments, agreed with those derived by quan-
tum mechanics calculations, revealing a difference of one order
of magnitude between the monofluorinated and the trifluori-
nated analogues,79 as schematized in Fig. 11. The results from
these studies offer the opportunity to exploit sugar fluorination
as a strategy to enhance fundamental intermolecular inter-
actions, with the consequent implications in drug design.
4.2 Hydrogen bonding
One of the earliest applications of replacement of sugar hydro-
xyl groups by fluorine concerned investigations of the role
of that hydroxyl group in the interaction with the protein.
An unchanged binding affinity was interpreted as the OH group
acting as a hydrogen acceptor or not participating in the
interaction, whilst a much reduced affinity was interpreted to be
caused by the loss in hydrogen bond donation from the ligand,
providing information that can be used for ‘epitope mapping’.22–25
However, the high ionisation potential of organofluorine lone pairs
makes fluorine only a weak hydrogen bond acceptor.80 In general,
the stronger hydrogen-bond (HB) acceptor groups present in
carbohydrates, as well as in water solvent, will be preferentially
involved in intra- or intermolecular HB formation over C–F
groups, whether in solution or in the solid phase. In crystal
structures, where the resulting structure is a balance of many
types of strong and weak interactions, it is not uncommon to
see C–F bonds ‘ignored’ in hydrogen bonding networks, even
for sugars with multiple C–F bonds.81
This has been applied for the partial disruption of the dense
hydrogen bonding network of polysaccharides such as cellulose,
which is responsible for its mechanical and structural properties.
Incorporation of two 3-deoxy-3-fluorinated glucose residues in a
hexamer has led to more soluble analogues.82
In the absence of stronger hydrogen bond acceptors, intra-
molecular hydrogen bonding to fluorine in fluorinated carbo-
hydrate derivatives has been demonstrated. In the solution
phase, this is often apparent by the presence of a coupling
constant between the alcohol hydrogen and the fluorine group
Fig. 11 Modulation of the CH–p stacking interactions by diverse fluorina-
tion patterns. Free energy differences among the different fluorinated and
not fluorinated derivatives in the WGA complexes were determined by
STD-NMR competition experiments.
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(h1JOH–F, with the h1-prefix indicating hydrogen bond between
the coupling partners).83 For example (Fig. 12), there is a 7.5 Hz
coupling between the axial C2–OH and C4–F in the L-ribopyr-
anose derivative 4.5,84 indicating a 6-membered ring intra-
molecular hydrogen bond. In 1,6-anhydro derivatives, this
coupling is reduced due to the longer distance between the
OH and the F groups (cf. 4.6).85 Hydrogen bonding between
vicinal fluorohydrins is weaker and h1J- are not always observed.
An interesting case is 4.7,34b whose alcohol hydrogen displays a
coupling constant to each fluorine atom, with a large 12.4 Hz
3JH–OH coupling indicative of the antiperiplanar orientation
between the two coupling partners. Interestingly, fluorosugars
have been used as probes to study intramolecular hydrogen
bonding to fluorine.85,86
Crystal structures of protein-F–carbohydrate complexes
often feature intermolecular hydrogen bonding contacts invol-
ving fluorine.87,88 The first example of a crystal structure
involving a fluorinated trisaccharide 4.9 (Fig. 13)87 nicely
showed how deoxyfluorination at the galactose 2-position lead
to a very similar ligand conformation.
However, deoxyfluorination can also lead to incorporation of
extra water molecules in the binding site. This has been
illustrated by crystal structure analysis of the 6-deoxy-6-fluoro-
D-galactose 2.6 complex with the arabinose binding protein
(Fig. 14b), compared to that of the natural ligand (Fig. 14a).88
It was proposed that the repulsion between the fluorine atom
and the carboxylate group caused a reorganisation, creating
space for a water molecule which, in turn, enables hydrogen
bond donation to the carboxylate group (which was lost upon
6-deoxyfluorination). In such cases, the energetics of binding
are complicated, which has repercussions for ‘epitope mapping’
experiments.88
An interesting case has also been reported when replacing
CHOH groups in UDP-galactopyranose 4.10 by CF2 moieties
leading to 4.11 (Fig. 15).89a This substitution has also been
shown to lead to additional intermolecular hydrogen bonding
interactions involving the fluorine atom that replaced the
hydrogen at C3 of 4.10,89a which may have contributed to
the increased affinity of this analogue compared to the native
ligand.89b
A similar case can be observed for the fluorinated maltose
3.19, already mentioned in Fig. 9, in complex with GlgE1
(Fig. 16). The guanidinium group of Arg392 forms a bidentate
hydrogen bonding interaction with the CF2-group in 3.19, while
for 3.18 (as covalent complex with GlgE1) this residue forms a
bidentate hydrogen bond with the fluorine and the anomeric
oxygen.63,64
In a very original application, fluorine introduction has been
successfully used to promote water binding in protein–carbo-
hydrate complexes. Bridging water between the GlcNAc and
threonine residues of Thr-containing glycopeptides was sus-
pected to play an important role in binding to the anti-MUC1
antibodies (SM3), but never observed in crystal structures of
4.12 (Fig. 17) with SM3.90 It was hypothesised that GlcNAc
residues featuring fluorinated amides may provide a more
hydrophilic environment leading to stabilisation of water mole-
cules. Calculations supported the presence of a hydrogen bond
between the water and the fluorine. Indeed, crystal structures
involving such fluorinated glycopeptides 4.13 and 4.14 did
show bridging water molecules although the weak electron
density of the fluorine atoms did suggest free rotation and hence
did not support the presence of the F  HO hydrogen bond.
Fluorine introduction will also influence hydrogen bonding
capacities of the adjacent hydroxyl groups. So far, this has only
been studied in non-carbohydrate model compounds, using
alcohols and a standard acceptor (N-methyl pyrrolidinone).91
While, as expected,92 the electron withdrawing character of
fluorine enhanced the hydrogen bond donating ability (also
termed hydrogen bond acidity), the intramolecular hydrogen
bonding to the fluorine atom actually leads to a reduced
hydrogen bond acidity.93
4.3 C–F  CQO and related interactions
The occurrence of orthogonal C–F  CQO arrangements was
discovered during seminal studies involving a fluorine scan
of thrombin inhibitors.94 The subsequent crystallographic
Fig. 12 Intramolecular OH  F hydrogen bonding in some fluorinated
carbohydrate derivatives.
Fig. 13 Crystal structure featuring intermolecular F  H2O hydrogen
bond interactions.
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database analysis pointed out the wider importance of this type
of interaction, which was also identified for C–O(H)  CQO.95
The shorter the C–F  CQO contact, the more the C–F bond
preferred to be positioned directly over the carbonyl carbon
close to the carbonyl pseudotrigonal axis. Originally suggested
to be a dipole interaction, other types such as n - p* and
p–hole interactions have also been proposed,96 but will herein
be referred to as a dipolar interaction. The C–F  CQO inter-
action is weakly stabilizing and amounts to ca. 1 kJ mol1.97
While C–H for C–F substitution in small bioactive molecules
usually leads to affinity increases, it must be emphasized that
other factors (for example, increase in lipophilicity) may also
contribute as well.17,98
To the best of our knowledge, a direct comparison of
C–O(H)  CQO and C–F  CQO interactions is not available
yet. However, examples of the latter contacts in protein X-ray
structures bound to fluorinated sugar derivatives have been
described. For example (Fig. 18), the crystal structure of the
bacterial heptosyltransferase WaaC in complex with a competitive
inhibitor, ADP-2F-heptose 4.15, displays a clear C–F  CQO inter-
action involving the Gly263/Thr262 linkage (d = 2.95 Å, F  CQO
100.61).99,100
Fig. 14 Sugar deoxyfluorination causing perturbation of glycan–lectin interactions: replacing a C–OH by a C–F bond allows incorporation of a new
water molecule and formation of a new water-mediated hydrogen bond.
Fig. 15 UDP-galactopyranose 4.10 and its tetrafluorinated analogue 4.11
in complex with UDP-galactopyranose mutase: replacing CHOH by CF2
allows formation of new water-mediated hydrogen bonds.
Fig. 16 Comparison of CHF and CF2-motifs present in maltose fluorides 3.18 (left) and 3.19 (right) in complex with GlgE1 (PDB codes 4CN4 and 4U2Z).
63,64
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An interesting case arises for CHOH to CF2 replacement,
which formally includes a C–H to C–F modification. This
substitution was shown to allow for the establishment of an
extra dipolar interaction. Fittingly, this feature has been
depicted (Fig. 19) in the crystal structures of the mycobacterial
galactose mutase UGM with Galp-UDP 4.10 and its tetrafluori-
nated derivative (4.11),89a which are very similarly positioned
within the UGM binding site.89a The axial C–H group at the
2-position of galactose is replaced by a C–F bond, which is
engaged in such an interaction with the carbonyl group of the
FAD cofactor.
4.4 Polar hydrophobicity
The term ‘polar hydrophobicity’ was coined by DiMagno to
capture the hydrophobic character of fluorine while possessing
a large (C–F) dipole moment.37,101 In essence, while fluorine
introduction can cause an increase in lipophilicity, it also allows for
possible attractive dipole-mediated interactions, and the directional
nature of the C–F dipole combined with the presence of multiple
chiral centres make ‘polar hydrophobicity’ a useful concept.
A compelling example is provided by the glycogen phosphorylase
fluorinated inhibitors shown in Fig. 20.22
The inhibition constants of D-glucose 4.16 and 2-deoxy-
2-fluoro-D-glucose 2.1 were similar. Compared to 4.16, the
b-glucosyl fluoride 4.17 displayed a lower affinity, while the
a-anomer 4.18 showed a higher affinity. Given that deoxyfluori-
nation at the 2-position has little effect, similar low inhibition
constants for 4.19 and 4.20 were expected. However, in each
case, a significantly reduced value was found. Strikingly,
the stereochemistry of the dideoxydifluorination proved to be
important since the corresponding 1,2-dideoxy-1,2-difluoro-
mannoses 3.1 and 4.22 exhibited a much decreased inhibition
potency (more than two orders of magnitude), and merely deoxy-
genation (as in 4.21) led to lower binding. Therefore, according to
the ‘polar hydrophobicity’ concept, the increased lipophilicity of
the dideoxy-difluorinated glucoses may indeed increase affinity,
but only when the C–F dipoles are correctly oriented (as in
4.19 and 4.20).
Fig. 17 Fluorinated glycopeptides used in binding studies with MUC1
antibodies.
Fig. 18 Dipolar interactions of the fluorine atom of ADP-2F-heptose 4.15
with heptosyltransferase WaaC (PDB 2H1H).99,100 See text for discussion.
Fig. 19 CHOH for CF2 exchange allows introduction of an unexpected
dipolar interaction.89a
Fig. 20 The enhanced affinity for glycogen phosphorylase of vicinal
dideoxy-difluorinated carbohydrates.22
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5 Fluorinated sugar derivatives as
probes
5.1 Introduction
In this section, the focus is set on the use of 18F and 19F
isotopes as bioanalytical probes for the study of kinetic trans-
port phenomena, lectin–carbohydrate interactions or for in vivo
imaging of tumors and drug distribution to name a few
examples. The analytical methods employed to detect fluori-
nated carbohydrates cover 19F-NMR, 19F magnetic resonance
imaging (MRI) and 18F positron emission tomography (PET).
With 100% natural isotopic abundance, but low natural
presence in biomolecules, its small size and large spectral
resonance range of ca. 200 ppm, 19F is an attractive probe for
studying metabolism and transport of biomolecules, including
carbohydrates, by NMR spectroscopy.102 The fluorine atom has
been used to substitute hydroxyl groups, protons or aldehydes
giving rise to a C–F functional group that lies between the C–H
and the C–OH in size, is chemically inert, retains the electro-
negativity of a hydroxyl group but loses its hydrogen donor
capacity. This hydroxyl/fluorine exchange allows an evaluation
of the contribution of individual hydrogen bonds in carbohy-
drate–protein binding events.21–25,102
5.2 Membrane transport studies
Due to its excellent spectral range and the absence of back-
ground peaks in biological matrices, high resolution 19F-NMR
is an ideal technique for studying kinetics and mechanism of
carbohydrate metabolism and sugar–protein binding in vitro.
This is the case for the glucose (Glu1) transporter mediated
transport of D-glucose over the erythrocyte membrane, which
has been studied by 19F-NMR and 19F-2D-EXSY-NMR by
various groups over the years as a model for the development
of glucose analogues for imaging and tumor targeting
applications.34a,103,104 Both techniques take advantage of the
shift to higher frequencies of fluorine resonances when moving
from an extracellular to an intracellular environment.103 Where
signal overlap between intra- and extracellular signals hinders
peak integration, 19F-2D-EXSY-NMR can provide the required
resolving power, with the intensity of cross peaks directly
proportional to the flux.103,105
Initial investigations with 2- and 3-deoxy-3-fluoro-D-glucose
(2.1, 5.1, Fig. 21) showed uptake rates similar to glucose and a
generally enhanced transport of the a-anomer,105 while the
transport of the 4- and 6-deoxyfluoro analogues (5.2, 5.3) was
only half of that of glucose.104 In contrast, higher fluorinated
compounds like the hexafluoroglucose racemic analogue 5.4
were shuttled over the erythrocyte membrane with an order of
magnitude higher transport efficiency compared to glucose.34a,101
However, a later synthesized trifluoroderivative of glucose 3.2
showed an overall decrease efflux efficiency to about 70%
compared to 5.1, used as a reference.103
Fluorinated fructose derivatives have been studied in
GLUT2/GLUT5 mediated membrane transport, which is of
relevance in breast cancer cell lines (2.1 is not transported by
GLUT5). Clear dose-dependent inhibition of [14C]-D-fructose
and -glucose by 6-deoxy-6-D-fluorofructose 5.5 (Fig. 22) was
shown, with very low Ki values, indicating 5.5 binds to both
transporters.106 Furthermore, by using [14C]-5.5, it could be
demonstrated that actual transport into the cells is occurring.
Similar results were found for the 3-deoxy-3-fluoroderivative 5.6
and for the fluorinated 2,5-anhydromannitol derivative 5.7.107
5.3 Lectin–carbohydrate interactions
19F-NMR spectroscopy has been extensively used for studying
lectin–sugar interactions19–21 either employing 19F as a mere
analytical probe or as an obvious method of choice for the
analysis of fluoroglycomimetics designed for an enhanced
interaction with the target protein. Allman et al. claimed that
until 2009 most fluorinated carbohydrates showed lower affinity
to lectins than their natural ligands.87b However, they completed
the synthesis of a series of fluorinated sialylactosamine analogues
and found similar or slightly higher binding affinity to the
receptor TgMIC1 of the pathogen Toxoplasma gondii.87b The
structural analysis of interaction of the fluorinated derivatives
5.9 and 4.9 (Fig. 23) with the TgMIC1 receptor showed a
F-mediated hydrogen bond (see Section 4.2) that was also corro-
borated by 19F NMR. In fact, a shift to lower field of the 19F
resonance was observed upon binding. Since monovalent carbo-
hydrate–protein interactions usually do not lead to a measurable
change in chemical shifts or line widths, the observed shift for
fluorinated sialyl-lactosamine analogue 4.9 is remarkable.87b
Diercks et al. have developed an innovative 19F-STD NMR
technique with greatly improved sensitivity for detecting binding
events over the conventional 19F-NMR methods based changes of
chemical shift.108 The interaction between Con A and 2-deoxy-2-
fluoro-D-glucose 2.1 was used as model to develop a 19F-STD NMR
Fig. 21 Selection of fluorinated monosaccharide structures employed in 19F-NMR spectroscopy for studying GLUT1-mediated glucose transport.
Fig. 22 Fluorinated fructose analogues for the study of GLUT2 and
GLUT5 transport.
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methodology that avoids the quantification problems that existed
with standard NMR methods19 and with previous versions of the
19F-STD NMR experiment,108 due to the requirement of J-coupling
between the STD accepting hydrogen and the fluorine nucleus.
Alternatively, a T2-relaxation
19F-NMR-based method109 has
been used to evaluate the interaction features and molecular
insights of a small library of monofluorinated monosac-
charides towards DC-SIGN, a calcium-dependent C-type lectin
of biomedical interest, involved in viral infections. The method
allowed the robust screening of a library of compounds, also
permitted obtaining key information on the specific sugar–
protein interactions, including the sugar hydroxyls involved in
the coordination to the calcium atom. Moreover, a new binding
mode of DC-SIGN to mannose through hydroxyl groups OH2
and OH3 was detected, along with the non ambiguous demon-
stration of the direct interaction of the lectin with Gal moieties,
with implications for recognition of larger oligosaccharides,
such as the histo blood type antigens.109
Also in the C-type lectin field, 19F R2-filtered NMR experi-
ments have been employed within a fragment-based drug
discovery program to determine novel Langerin ligands.110 In
particular, the ManNAc analogue 5.10 (Fig. 24) was used as spy
molecule in competitive binding assays versus a library of
2-deoxy-2-carboxamido-a-mannoside analogs 5.11, in which
different molecular fragments were placed instead of the CF3
moiety. The analogues were initially chosen by virtual screening
and the best hits were subsequently synthetized and submitted
to the 19F R2-filtered NMR assay, which afforded the corres-
ponding KI values in a fairly straightforward manner. Small,
negatively charged substituents were found to substantially
increase the affinities towards Langerin.110
19F-NMR experiments have also been used to analyse the
recognition of fluorinated mannose-containing oligosac-
charides by cyanovirin-N, a mannose binding anti-HIV lectin.
In particular, the Mana(1 - 2)Man and Mana(1 - 2)Mana-
(1 - 2)-Man oligosaccharides showing a 2-deoxy-2-fluoro-a-D-
mannopyranosyl unit at the non-reducing end (5.12 and 5.13,
respectively, Fig. 25) were employed to evaluate the binding
mode and to determine the kinetic and thermodynamic para-
meters of the interaction, which were further assessed through
1H–15N HSQC-based chemical shift perturbation analysis and
ITC measurements. 2D 19F–19F exchange experiments also
allowed detecting an additional binding mode for the tri-
saccharide, which could not be detected using regular 1H-based
NMR experiments.111
5.4 18F labeled sugars for PET imaging
5.4.1 Introduction to PET. PET imaging has important
applications in cancer diagnostics, neuroimaging, cardiology,
biodistribution studies and for establishing pharmacokinetics
of novel compounds during drug development.112 2-Deoxy-2-
fluoro-D-glucose 2.1 (Fig. 26) is the most common PET tracer in
clinical use for neuroimaging and tumor diagnostics, taking
advantage of the high glucose metabolism in both brain and
cancer cells. It is broadly used for the staging of tumors,
localization of metastasis, and as a monitoring method for
treatment and the identification of reoccurring tumors after
treatment.112 In cardiology, 2.1 is helpful for the stratification
of patients that would benefit from a bypass surgery.
The wide availability of 2.1 has prompted its use for the
synthesis of related compounds, as (18F) labeled lactose,113
UDP-(18F)-2-deoxy-2-fluoro-D-glucose114 or tags to facilitate
tracking of other biomolecules via PET.115,116 Wuest et al. has
employed maleimidehexyloxime 5.7 as a reagent for tagging
peptides and proteins after reaction with 2.1. As model,
Fig. 23 The sialylactosamine derivatives employed for studying interactions with the TgMIC1 receptor by 19F-NMR spectroscopy.
Fig. 24 Spy molecule used in competitive binding assays of ManNAc
analogues.
Fig. 25 Fluorinated mannose-containing oligosaccharides.
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annexin 5, presenting a single cysteine, was labeled with 5.14
in 43–58% decay-corrected yield and its biodistribution and
kinetics studied in a small animal xenograft tumour model.116
In a similar fashion, Boutureira et al. tagged proteins presenting
accessible cysteine residues with (18F)2-deoxy-2-fluoro-D-thio-
glucose 5.15 via disulfide or thioether linkages,117 while
Maschauer et al. reported a slightly different approach for
labeling two short peptides employing the [18F]-2-FGD-azide
5.16.118 Uptake and activity of the novel probe 5.17 and other
derivatives was demonstrated in vitro on neurotensin receptor
(NT-receptor) expressing cells and by autoradiography of rat
brain slices, which showed an accumulation of the (18F) labeled
probe in NT-receptor rich areas. Biodistribution studies in a
nude xenograft mouse model with 5.17 showed rapid blood
clearance, specific uptake by the kidneys with low uptake by
other organs, showing sufficient signal to noise ratios for PET-
scanning shortly after injection. Biodistribution of the glycosy-
lated RGD peptide (18F)-2-deoxy-2-fluoro-D-glucose-RGD 5.18
showed a similar blood clearance but 3 times higher uptake by
liver and kidney compared to the galactose analogue. With a good
tumor/blood ratio of 2.4 and excellent metabolic stability 5.18
seems as a promising tool for future avb3-integrin imaging by PET.
Essentially the same approach for the labeling of proteins
with 2-deoxy-2-(18F)fluoro-D-glucose via a triazole linkage was
reported by Boutureira et al.119 Coupling of [18F]2-FDG azide
5.16 was achieved via copper catalyzed cycloaddition to the
alkyne function of recombinant model protein with the non-
canonical amino acid propargylglycin selectively incorporated
via expanded genetic code methodology.120
2-Deoxy-(18F)fluoro mannose 5.19 (Fig. 27) displays similar
uptake profile as glucose and like 2-deoxy-2-fluoro-D-glucose it is
not further metabolized after phosphorylation by hexokinase-1.121
Furumoto et al. synthesized 5.19,122 which showed a rapid
cell uptake comparable to that of 2-deoxy-2-fluoro-D-glucose,
with formation of a compound likely to be 2-deoxy-2-fluoro-
D-mannose-6-phosphate. A biodistribution study in a tumor
mouse model showed high uptake in tumor cells, relatively
high uptake in brain and lower uptake in other tissues, which
might provide an advantage for 2-deoxy-2-fluoro-D-mannose for
imaging of brain tumours.122
6-Deoxy-(18F)-fluorogalactose 2.6 (Fig. 28) has been synthe-
sized as a PET tracer to study galactose metabolism in vivo,123
being incorporated 6 times faster into glycoconjugates than
galactose itself.124,125 In contrast, 2-deoxy galactose is, in fact, a
inhibitor of N-glycan synthesis with a similar potency as
tunicamycin.124 However, it is taken up by the liver at a very
high rate where it is phosphorylated and further converted to
UDP-2-deoxy-2-(18F)fluoro-D-galactose 5.20, making it a viable
tracer to study galactose metabolism.126
Based on the attractiveness of trehalose analogues as probes
for bacterial infection imaging,127 Swarts demonstrated the
selective uptake of 2-deoxy-2-(18F)fluorotrehalose 5.21 (Fig. 29)
in Mycobacterium smegmatis, a non-pathogenic model organism
for M. tuberculosis.112d
The importance of sialic acid as a terminal recognition
element on larger oligosaccharides and the overexpression of
sialylated structures on tumor cells have prompted interest in
developing PET tracers to study sialic acid metabolism (Fig. 30).
N-Acetyl-3-(18F)fluoro sialic acid (18F)-2.4 and N-acetyl-2-deoxy-
2,3-(18F)difluorosialic acid 5.22 showed insufficient uptake to
be of any use as PET tracer, probably due to the lack of
membrane based sialic acid transporters and charge repulsion
between the negatively charged membrane and the sialic acid
derivatives.128,129
Fig. 26 Labeling based on 2-deoxy-2-fluoro-D-glucose 2.1.113–118
Fig. 27 18F-Labeled mannose.
Fig. 29 Labeled trehalose as probe for bacterial infection.112d
Fig. 28 18F-Labeled galactose derivative for the study of galactose meta-
bolism by PET.
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The peracetylated 2-deoxy-azido mannosamine 5.23 is a
convenient sialic acid precursor widely employed for in vivo
imaging of sialic acid integration into cell surface proteins by
metabolic glycoengineering.130 Hartlieb et al. have developed
synthetic routes towards non-radioactive 3-deoxy-fluoro-N-acetyl
mannosamine 5.24, the precursor for CMP-7-deoxy-fluoro sialic
acid 5.25.131
The synthesis of a 5-deoxy (18F)-fluoro ribose ((18F)FDR) 5.28
has also been achieved (Fig. 31)132,133 from S-adenosyl-L-
methionine (SAM) 5.26. Subsequent hydrolysis of the nucleo-
side by a nucleosidase from Trypanosoma vivax (TvNH) pro-
duces the free radiolabeled (18F)-fluoro ribose 5.28 with decay
correction in approximately 3 h.
A biodistribution study has established (18F)FDR 5.27 as a
suitable probe for PET imaging.133
5.5 19F MRI
Magnetic resonance imaging (MRI) is a radiation-free medical
imaging modality that generates three-dimensional body images
with anatomical detail for the detection of disease and monitoring
treatment outcomes and excellent contrast for soft tissues.134,135
The relatively low sensitivity of MRI can be enhanced by the use of
contrast agents.136 A huge gain in sensitivity is potentially
also possible by employing fluorinated compounds as contrast
agents.137 MRI however, has a 1000-fold lower sensitivity than PET
and requires millimolar concentrations of fluorinated reporter
molecules.136,137 Polyfluorinated sugars have been far less
explored as contrast agents. Sufficient contrast can be obtained
by employing labeled polysaccharides138 or functionalized
nanoparticles137 as reporter molecules or also employing high
concentrations of mono-fluorinated small molecules.139 Poly-
meric carbohydrates show suitable properties as scaffolds for
the development of MRI contrast agents.138 Krawczyk et al. labeled
with fluorine a series of natural polysaccharides and evaluated
their properties as MRI contrast agents in cell and in vivo.138
Another strategy to increase fluorine density is the presentation of
multiple fluorinated ligands on the surface of nanoparticles.137
Finally, 3-FDG has been used for in vivo brain imaging.139
Although 3-FDG is phosphorylated by hexokinase 300 times
slower than its isomer 2-FDG, it was found to be a better substrate
for the aldose reductase than D-glucose itself. Consequently, it
may be employed as functional probe for the non-invasive study
of glucose metabolism via the aldose reductase sorbitol (ARS)
pathway.
6 Applications
Section 5 has focused on the use of the fluorine-containing
compounds as probes to monitor molecular interactions.
We herein focus on their applications to monitor, modulate,
and interfere with biological activities.
6.1 Fluorine-containing sugars as inhibitors and chemical
probes
6.1.1 Fluorosugars as in cellulo glycosyltransferase inhibitors.
Glycosyltransferases (GT) catalyze the assembly of oligosaccharides
and the glycosylation of aglycone acceptor substrates, such as
lipids or proteins. They usually use a nucleotide-sugar as
an activated sugar donor substrate. Due to their biological
relevance, their inhibition has been the topic of intense
research.140 Fluorinated analogues, (Fig. 32) including 6.1,141
have played a major role in this field because they provide
molecular tools to allow the analysis of the interactions
between the activated donor and the enzyme. Fluorinated
phosphonate of general structure 6.2 and 6.3 have been also
developed either as non-hydrolyzable analogues of glycosyl-1-
phosphates (6.2) or as transition state analogues (6.3)142 of GTs
or, more generally, enzymes processing carbohydrates phos-
phorylated at the anomeric position.64,143 Nucleotide-sugars
Fig. 30 Fluorinated structure for studying sialic acid metabolism by PET.
Fig. 31 Radiolabeled ribose derivatives as tracers for studying ribose metabolism via PET (17–19), radiotracer 2-FDM, and precursor molecules.
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fluorinated at the 3-, 4-, 5- or 6-position of the sugars have also
been synthesized as enzymatic probes,52,56,144 and have been
successfully applied as chain terminator agents of polysaccharide
biosynthesis.145
In molecules 6.1, the electron-withdrawing character of the
fluorine atom is believed to destabilize the transition state of
the glycosylation reaction, which likely displays a substantial
cationic character. Nucleotide-sugars 6.1 are thus donor sub-
strates that are too slow for the enzymatic reaction to be
observed, but that maintain the usually high affinity (low mM
Km) of the natural substrates.
141c,146 Thanks to this stability,
XRD 3D-structures of GTs could be obtained in complex
with nucleotide-fluorosugars 6.1, thus revealing the intimate
contacts between the donor substrate and the enzyme.147
However, the very interesting inhibitory properties of mole-
cules 6.1 could not be translated to in vivo applications or even
in cell-based bioassays due to their inability to cross cell
membranes. Such a limitation has recently been overcome
thanks to a prodrug approach: indeed, it was shown that some
precursors of 6.1 can be transported across the cell membrane.
Once in the cytoplasm, they are enzymatically transformed into
the fluorinated sugar-nucleotide, thus generating a GT inhibi-
tor in situ. For instance, peracetylated 3-fluoro-sialic acid 6.4148
crosses the membrane of mammalian cells and is transformed
into nucleotide-sugar 6.5 after intracellular enzymatic ester
hydrolyses and CMP-transfer (Fig. 33), thus shutting down
sialylation in cellulo.148 The same team demonstrated later
on that the administration of 6.4 in mice dramatically
decreased sialylated glycans in cells of a large set of tissues
and resulted in deleterious effects on liver and kidney
functions.149 The group of Adema then studied the effect of
prodrug 6.4 on cancer cell lines, in vitro and in vivo, and showed
reduced tumor growth and metastasis.150 A second generation
of fluorinated pro-inhibitors 6.6 were then synthesized with a
carbamate at C-5. The SialT inhibitory activities of the latter
molecules 6.6 were found to be prolonged and enhanced
thanks to a more efficient intracytoplasmic transformation into
their nucleotide sugar active form.151 Interestingly, bacterial
SialT can also be inhibited using the same prodrug approach,
but this time the deprotected fluorinated pro-inhibitor 2.4
has to be used instead of 6.4. In pathogenic non-typeable
Haemophilus influenzae, molecule 2.4 is taken up by the ATP-
independent periplasmic transporter system. Its intracellular
transformation into 6.5 triggers an inhibition of sialic acid
incorporation into the bacterial lipo-oligosaccharide (LOS)
resulting in enhanced serum-mediated killing.152
Given the biological relevance of fucosyltransferases
(FucTs),140 the in cellulo generation of 2-deoxy-2-fluoro-fucose-
GDP141c,d 6.9 has been thoroughly studied by the same prodrug
approach.148 The fluoro-fucoside 6.8 is an orally active inhibitor
of protein and cellular fucosylation153 that was shown to
inhibit several biological functions in transgenic sickle mice.154
Fig. 32 Fluorinated nucleotide-sugars as enzyme inhibitors or inactivators.
Fig. 33 In cellulo generation of mammalian Sial-T global inhibitor 6.5.
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Importantly, it was shown that the accumulation nucleotide-
sugar 6.9 into the cells not only inhibit FucTs, but also shut
down the biosynthesis of GDP-fucose, the natural FucT donor.148
A recent application of this fucosylation blockade has
focused on the generation of non-fucosylated recombinant
antibodies in CHO cells.155 Peracetylated fucostatin can be
taken up in mammalian cells and enzymatically hydrolyzed
to generate fucostatin 2.3156 (Fig. 34A) a 6,6,6-trifluorinated
analogue of L-fucose. The latter is then transformed into GDP-
fucostatin which blocks protein fucosylation by inhibiting the
GDP-fucose de novo biosynthesis. Indeed, a cocrystal structure
proved that GDP-fucostatin binds an allosteric site of GDP-
mannose 4,6-dehydratase. This result can find important
applications in the generation of non-fucosylated therapeutic
antibodies. The latter have been shown to display an improved
antibody-dependent cellular cytotoxicity, thus resulting in a
better in vivo efficacy, which is a key parameter for instance
in oncology clinical trials. The same strategy was later on
exploited for the production of low-fucosylated monoclonal
antibodies from murine hybridoma cells.157 In the galactose
series, mono and difluorinated galactosides of general structure
6.10 (Fig. 34B) were shown to inhibit UDP-galactose biosynthesis
in epithelial cells and fibroblasts, resulting in a metabolically
induced galactosemic phenotype.158
Very recently, a monofluorinated analogue of 2,4-diacet-
amido-2,4,6-trideoxygalactose, which is exclusively found in
bacteria, has been shown to dramatically reduce Helicobacter
pylori’s ability to synthesize glycoproteins and led to dimin-
ished growth, motility, and biofilm formation.159 The proposed
mode of action was here again the in situ generation of a
glycosyltransferase inhibitor.
6.1.2 Fluorosugars as fluorescent probes of glycosidase
activity and viral neuraminidase inhibitors. 2-Fluoro deoxy
sugars have become essential and classical tools for studying
the mechanism of glycosyl hydrolases, especially those pro-
ceeding by retention of anomeric configuration.62c This class of
fluorinated molecules are not only interesting biochemical
mechanistic probes, they also constitute nowadays powerful
tools either as biological probes but also as potential drugs.
In particular, and as discussed in Section 3.3, the different
stabilities of fluorine-containing glycomimetics of sialic acid
has been exploited for the design of selective mechanism-based
glycosidase inhibitors.66,67 The most significant results have
been obtained with 2,3-difluorosialosides (DFSA) such as those
illustrated in Fig. 35, designed as mechanism-based inhibitors
of Trypanosoma cruzi transsialidase (TcTs).160 However, in
2013, the Wong group developed DFSA 6.11 bearing an alkyne
functional group at the 5-position was found to be an irrever-
sible inhibitor of viral, bacterial and human sialidases,161
permitting to show that tyrosine residues play the role of
catalytic nucleophiles, as for TcTs. A cell-permeable ester
protected analogue of 6.11 could be used in cell-based assay
for in situ imaging of sialidase activity. The same year, Withers
et al. published a novel series of DFSA of general structure
6.13 that proved to be potent and broad-spectrum covalent
inhibitors of influenza neuraminidase.162 These fluorosugars
function both in cell-based assays and animal models. Inter-
estingly, it was shown that the configurations of the two C–F
bonds of 6.13 strongly impact both the enzymatic activity and
the hydrolysis rates of the DFSAs. Importantly, the analysis of
the 3D structures of neuraminidase in complex with 6.13
evidenced attractive interactions between an equatorial fluor-
ine at C-3 and an arginine residue but not with its axial
epimer.163 By playing with structural modifications at C-4 and
C-5, it was thus demonstrated that DFSA 6.14 was a selective
covalent inhibitor of human parainfluenza virus type 3.164 Later
on, 3-fluorosialosides 6.12 bearing a fluorogenic group at the
anomeric position were shown to be ultrasensitive reagents to
titrate neuraminidases including in biological media.165
Mechanistically, it is worthy mentioning that all the catalytic
nucleophiles of the sialidases targeted by DFSAs 6.11–6.14 are
always tyrosines.
6.1.3 Polyfluorinated sugars in chemical biology: cell
uptake and enzyme binding. Synthetic methodologies have also
been developed for the introduction of several fluorine atoms
onto a carbohydrate scaffolds (Fig. 36) with emphasis in chemical
biology.166 A key question has been addressed167 by Linclau,
Turner, and Flitsch: can these heavily fluorinated molecules be
substrate of a biologically relevant enzyme? Indeed, the tetra-
fluorinated galactomimetic 6.15 was a substrate of galactose
Fig. 34 In cellulo generation of (A) fucosylation inhibitors 6.9 and GDP-fucostatin (B) galactose-1-phosphate uridyltransferase inhibitors.
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oxidase, with a loss of affinity compared to D-galactose.168
Tetrafluorination of sugars has also been explored as a way to
generate competitive enzyme inhibitors. As leading examples,
glucose analogues 6.16 and 6.17 have been investigated as
b-glucosidase inactivators,168 while the nucleotide-sugar analo-
gue 6.18 strongly inhibited UDP-galactopyranose mutase
(UGM) from Mycobacterium tuberculosis.89 Interestingly, as
already mentioned in Section 4.3, molecule 6.18 displayed a
better affinity for UGM than the two monofluorinated analogues
at C-2 and C-3. NMR and X-ray diffraction data revealed the
conformational features behind this enhanced affinity along
with the key polar and non polar interactions that take place
between 6.18 and the FAD cofactor of UGM.89 The tetrafluori-
nated glucose derivative 3.31 was shown to be a inhibitor for
the mutarotase enzyme.58
6.2 Synthetic vaccines and therapeutic antibodies
A particularly exciting application of fluorinated carbohydrates
is their incorporation in synthetic antitumour vaccine and
therapeutic antibodies.169 Synthetic vaccines with natural sugar
antigens tend to be sensitive to enzymatic degradation in vivo,
which can be overcome with fluorination (see Section 3.3).
Maintaining the immunological efficiency requires that the
fluorination does not negatively impact on the generation of
Fig. 35 2,3-Difluorosialosides as covalent sialidase inhibitors.
Fig. 36 Highly fluorinated carbohydrate analogues.
Fig. 37 Fluorinated sugars as part of synthetic vaccines and antibodies.
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the required type of antibodies, and that the thus generated
antibodies bind with the tumour cells.
The groups of Hoffmann-Röder and Kunz reported that
fluorinated Thomsen–Friedenreich (TF) conjugates such as
6.19 and 6.20 (Fig. 37) generated a very strong immune
response in mice, and their antibodies were shown to strongly
bind to the epithelial tumour MCF-7 cells.170 Later on,
Hoffmann-Röder showed that the antisera derived from the
immunizations against a broader range of TF-MUC analogues
fluorinated at the 6 and the 2-positions showed very little
differences in the binding to the fluorinated and non-
fluorinated antigens.170 These findings support the concept
of using fluorinated analogues of tumour-associated carbo-
hydrate antigen (TACA) for the design of synthetic vaccines.
In addition, Yang et al. showed that fluorinated STn (another
important TACA) antigens such as 6.22 and 6.23 significantly
improved antigenicity compared to the nonfluorinated 6.21,
and that the resulting antisera strongly reacted with STn
positive tumor cells.171
Interestingly, when 3-fluorinated sialic acids were incorpo-
rated in the monoclonal antibody rituximab (6.24), this glyco-
form showed similar binding and avidity to FcgRIIIa as
the nonfluorinated rituximab, further showing the potential
of fluorinated carbohydrates in the field of therapeutic
antibodies.68b
7 Conclusions and perspectives
Fluorinated carbohydrate derivatives have been used in glycos-
ciences, from glycochemistry to glycobiology, for over 30 years.28
The significant synthetic advances made in their synthesis, and in
their derivatization (including glycosylation) have cemented their
importance in glycobiology. This review provides an extensive
summary of the effects of carbohydrate fluorination both with
regard to changes in physical, chemical and biological properties.
The influence of fluorination on carbohydrate conformation,
with a focus on ring conformation, glycosidic bond and exocyclic
methylene group conformation is described.51 This includes a
comparison with C-glycosides and carbasugars.
The influence of fluorination on glycosidic bond stability
and how this has been exploited is described.60 Finally, the
novel direction of investigating carbohydrate lipophilicity is
included.71
The influence of fluorination on intermolecular interactions
is described in detail, both involving the C–F bond itself, as
well as involving adjacent functional groups and C–H bonds.76
The recent advances in fluoro-containing glycomimetics
synthesis,29 especially in terms of regio and stereo selective
fluorine substitution, together with the development of novel
strategies for biophysical characterization addressed the influ-
ence of fluorine in sugar/protein CH–p interactions and offer
opportunities to exploit sugar fluorination to modulate inter-
molecular interactions.78 The already widespread use of fluorine
in pharmaceuticals combined with strategic site-specific fluorine
substitution may further boost for a rational drug design that
combine the intrinsic advantages of drug fluorination with
enhanced binding affinity to the target protein receptors.
With the exception of 2-FDG the development of fluorinated
carbohydrate molecular imaging probes of PET112 and MRI137
has been less developed. Further investigation of other fluori-
nated monosaccharide isomers is likely to provide PET probes
with higher organ selectivity. On the other hand the develop-
ment of carbohydrate contrast agents for F-MRI has been
hampered by the difficulty of introducing a sufficient number
of chemically identical fluorine atoms in the probes and the
associated problems in solubility. Recent efforts employing
polysaccharide and oligosaccharide scaffolds might overcome
the current technical difficulties and provide carbohydrate
based contrast agents with additional targeting function.
From the enzymology viewpoint, fluorinated carbohydrates
have long been recognized as valuable tools for probing enzy-
matic mechanisms at the molecular level, for a wide range of
glycosyl-processing biocatalysts.141 During the last decade
novel strategies have emerged to generate in cellulo potent
fluorinated mechanism-based inhibitors, not only on whole
cell assays, but also in vivo. The latter developments open new
horizons in the development of drugs, for instance in the field
of infectious diseases.
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22, 651.
22 I. P. Street, C. R. Armstrong and S. G. Withers, Biochemistry,
1986, 25, 6021.
23 C. P. J. Glaudemans, Chem. Rev., 1991, 91, 25.
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Gabius, J. Jiménez-Barbero and P. Vogel, Chem. – Eur. J.,
2009, 15, 2861.
42 (a) K. Bock and J. O. Duus, J. Carbohydr. Chem., 1994,
13, 513; (b) K. N. Kirschner and R. J. Woods, Proc. Natl.
Acad. Sci. U. S. A., 2001, 98, 10541.
43 (a) L. D. Hall and L. Evelyn, Chem. Ind., 1968, 183;
(b) L. Evelyn and L. D. Hall, Carbohydr. Res., 1976, 47, 285.
44 L. Phillips and V. Wray, J. Chem. Soc. B, 1971, 1618.
45 M. Sharma, R. J. Bernacki, B. Paul and W. Korytnyk,
Carbohydr. Res., 1990, 198, 205.
46 J. St-Gelais, M. Bouchard, V. Denavit and D. Giguère, J. Org.
Chem., 2019, 84, 8509.
47 (a) J. F. Espinosa, F. J. Cañada, J. L. Asensio, M. Martı́n-
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A. Hoffmann-Röder, Beilstein J. Org. Chem., 2015, 11, 155.
68 (a) X.-L. Sun, Y. Kanie, C.-T. Guo, O. Kanie, Y. Suzuki and
C.-H. Wong, Eur. J. Org. Chem., 2000, 2643; (b) H.-J. Lo,
L. Krasnova, S. Dey, T. Cheng, H. Liu, T.-I. Tsai, K. B. Wu,
C.-Y. Wu and C.-H. Wong, J. Am. Chem. Soc., 2019,
141, 6484.
69 J. A. Arnott and S. L. Planey, Expert Opin. Drug Discovery,
2012, 7, 863.
70 (a) D. Bas, D. Dorison-Duval, S. Moreau, P. Bruneau and
C. Chipot, J. Med. Chem., 2002, 45, 151; (b) M. F. Mazzobre,
M. V. Roman, A. F. Mourelle and H. R. Corti, Carbohydr.
Res., 2005, 340, 1207.
71 B. Linclau, Z. Wang, G. Compain, V. Paumelle, C. Q.
Fontenelle, N. Wells and A. Weymouth-Wilson, Angew.
Chem., Int. Ed., 2016, 55, 674.
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M. Bosco, Y. Roué, F. Moreau, S. Grizot, A. Ducruix,
S. Escaich and S. P. Vincent, Chem. – Eur. J., 2008,
14, 9530; ( f ) M. D. Burkart, S. P. Vincent and C.-H. Wong,
Chem. Commun., 1999, 1525.
142 (a) L. Dumitrescu, G. Eppe, A. Tikad, S. El Bkassiny,
W. Pan, S. Gurcha, G. Besra, A. Arda, J. Jiménez-Barbero
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P. Sinaÿ and S. P. Vincent, Chem. – Eur. J., 2006, 11, 3114.
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